Clinical Trials

Title   16-207 - [923977-5] Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Description   The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.
IRB Number   16-207
Treatment   Oncology - Breast Cancer
Status   Active
Principal Name   Sachin Pai, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us